ES2346877T3 - Composicion y procedimiento para modular la interaccion de las celulas t y las celulas dendriticas. - Google Patents

Composicion y procedimiento para modular la interaccion de las celulas t y las celulas dendriticas. Download PDF

Info

Publication number
ES2346877T3
ES2346877T3 ES04078220T ES04078220T ES2346877T3 ES 2346877 T3 ES2346877 T3 ES 2346877T3 ES 04078220 T ES04078220 T ES 04078220T ES 04078220 T ES04078220 T ES 04078220T ES 2346877 T3 ES2346877 T3 ES 2346877T3
Authority
ES
Spain
Prior art keywords
cells
sign
icam
hiv
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04078220T
Other languages
English (en)
Spanish (es)
Inventor
Carl Gustav Figdor
Teunis Bernard Herman Geijtenbeek
Yvette Van Kooyk
Ruurd Torensma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radboud Universiteit Nijmegen
Stichting Radboud Universitair Medisch Centrum
Original Assignee
Radboud Universiteit Nijmegen
Stichting Radboud Universitair Medisch Centrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radboud Universiteit Nijmegen, Stichting Radboud Universitair Medisch Centrum filed Critical Radboud Universiteit Nijmegen
Application granted granted Critical
Publication of ES2346877T3 publication Critical patent/ES2346877T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
ES04078220T 1999-04-19 2000-04-19 Composicion y procedimiento para modular la interaccion de las celulas t y las celulas dendriticas. Expired - Lifetime ES2346877T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99201204 1999-04-19
EP19990201204 EP1046651A1 (en) 1999-04-19 1999-04-19 Composition and method for modulating dendritic cell-T interaction
US17692400P 2000-01-20 2000-01-20
US176924 2000-01-20

Publications (1)

Publication Number Publication Date
ES2346877T3 true ES2346877T3 (es) 2010-10-21

Family

ID=8240111

Family Applications (2)

Application Number Title Priority Date Filing Date
ES04078220T Expired - Lifetime ES2346877T3 (es) 1999-04-19 2000-04-19 Composicion y procedimiento para modular la interaccion de las celulas t y las celulas dendriticas.
ES00921181T Expired - Lifetime ES2307502T3 (es) 1999-04-19 2000-04-19 Composicion y procedimiento para modular la interaccion entre celulas dentrificas y linfocitos t.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES00921181T Expired - Lifetime ES2307502T3 (es) 1999-04-19 2000-04-19 Composicion y procedimiento para modular la interaccion entre celulas dentrificas y linfocitos t.

Country Status (13)

Country Link
US (4) US7148329B1 (enExample)
EP (3) EP1046651A1 (enExample)
JP (2) JP4989820B2 (enExample)
KR (3) KR100923340B1 (enExample)
AT (2) ATE398140T1 (enExample)
AU (1) AU776317B2 (enExample)
CA (1) CA2330231C (enExample)
DE (2) DE60044621D1 (enExample)
DK (2) DK1086137T3 (enExample)
ES (2) ES2346877T3 (enExample)
NZ (1) NZ508723A (enExample)
PT (2) PT1086137E (enExample)
WO (1) WO2000063251A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
US6515124B2 (en) * 2000-02-09 2003-02-04 Hoffman-La Roche Inc. Dehydroamino acids
KR100881471B1 (ko) * 2000-05-08 2009-02-05 셀덱스 쎄라퓨틱스, 인크. 수상세포에 대한 인간 모노클로날 항체
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
EP1339830A2 (en) * 2000-12-21 2003-09-03 Stichting Katholieke Universiteit Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
US20030013081A1 (en) 2001-06-26 2003-01-16 Olson William C. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
ES2197826B1 (es) * 2002-06-21 2005-04-01 Consejo Superior De Investigaciones Cientificas Compuesto terapeutico frente a la infeccion por leishmania y su uso.
US7691591B2 (en) 2002-09-20 2010-04-06 Stichting Katholieke Universiteit Methods of identifying and isolating cells expressing DC-sign
AU2003269389A1 (en) * 2002-09-20 2004-04-08 Stichting Katholieke Universiteit Antigen uptake receptor for candida albicans on dendritic cells
US20040146948A1 (en) * 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
AU2003301804A1 (en) * 2002-11-05 2004-06-07 Institut National De La Sante Et De La Recherche Medicale Dc-sign blockers and their use for preventing or treating viral infections.
US7427469B2 (en) 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
EP1417965A1 (en) * 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
CA2514979A1 (en) 2003-01-31 2004-09-02 Celldex Therapeutics, Inc. Antibody vaccine conjugates and uses therefor
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
AU2011211337B2 (en) * 2003-10-16 2014-10-02 Cancure Limited Immunomodulating compositions and uses therefor
AU2004281080A1 (en) 2003-10-16 2005-04-28 Stephen John Ralph Immunomodulating compositions and uses therefor
WO2005058244A2 (en) 2003-12-15 2005-06-30 Alexion Pharmaceuticals, Inc. Novel anti-dc-sign antibodies
WO2005092288A1 (en) 2004-03-19 2005-10-06 Let There Be Hope Medical Research Institute Carbohydrate-derivatized liposomes for targeting cellular carbohydrate recognition domains of ctl/ctld lectins, and intracellular delivery of therapeutically active compounds
US7884085B2 (en) * 2004-05-12 2011-02-08 Baxter International Inc. Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
EP2072040B1 (en) * 2004-05-12 2013-05-01 Baxter International Inc. Therapeutic use of nucleic acid micropheres
US20070020238A1 (en) 2005-06-01 2007-01-25 David Baltimore Method of targeted gene delivery using viral vectors
FR2895262B1 (fr) * 2005-12-22 2009-07-17 Lab Francais Du Fractionnement Inhibition de la reponse immunitaire anti-fviii
AT503387B1 (de) * 2006-03-27 2008-05-15 Univ Wien Pharmazeutische zusammensetzung zur vorbeugung von infektionen
BRPI0714495B8 (pt) * 2006-07-21 2021-05-25 California Inst Of Techn lentivírus deficiente para replicação recombinante pseudotipado
KR20090114430A (ko) * 2007-02-02 2009-11-03 베일러 리서치 인스티튜트 항원-제시 세포 상에서 발현된 ｄｃｉｒ에 대한 항원 표적화에 기초한 백신
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
WO2008097817A2 (en) * 2007-02-02 2008-08-14 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
BRPI0815848A2 (pt) * 2007-08-30 2017-06-06 The Burnet Inst composto, linhagem de célula que produz anticorpo estável, composição, métodos para modular uma resposta imune em um indivíduo e para tratar e/ou prevenir uma doença, usos de um composto e/ou uma composição e de células dendríticas ou precursores das mesmas, métodos para enriquecer e detectar células dendríticas ou um subconjunto ou precursores das mesmas, polipeptídeo, polinucleotídeo vetor, célula hospedeira, planta transgênica, animal não humano transgênico, extrato, processo para preparar um composto ou um polipeptídeo, população enriquecida de células dendríticas e/ou precursores das mesmas, população de célula dendrítica expandida e/ou precursores das mesmas, métodos para identificar uma molécula que se liga a um polipeptídeo e para triar quanto a um composto que se liga a um polipeptídeo, uso de um polipeptídeo, um polinucleotídeo, um vetor, uma célula hospedeira, uma planta transgênica, um extrato, uma população de célula e/ou uma composição, método para produzir um composto, e, kit.
AU2008319384A1 (en) 2007-10-29 2009-05-07 Virginia Tech Intellectual Properties, Inc. Porcine DC-SIGN , ICAM-3 and LSECtin and uses thereof
SG187482A1 (en) 2007-11-07 2013-02-28 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
EP2770061B1 (en) 2009-07-24 2018-10-24 Immune Design Corp. Non-integrating lentiviral vectors
JP5888728B2 (ja) * 2009-11-05 2016-03-22 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
JP5690132B2 (ja) 2010-06-17 2015-03-25 株式会社マーレ フィルターシステムズ エンジンの換気システム
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP3480316B1 (en) 2012-03-30 2022-09-14 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
DK2833914T3 (en) * 2012-04-04 2019-03-11 Vaxform Llc ADMINISTRATIVE SYSTEM FOR ORAL VACCINE ADMINISTRATION
US10196614B2 (en) * 2012-09-18 2019-02-05 University Of Washington Through Its Center For Commercialization Compositions and methods for antigen targeting to CD180
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
AU2015233084B2 (en) 2014-02-21 2020-12-17 Anokion Sa Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CA3185180A1 (en) 2014-05-16 2015-11-19 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
EP3318577A4 (en) 2015-06-30 2019-01-23 Osaka University ANTIPLEXIN A1 AGONISTANTIKÖRPER
CN108210503A (zh) * 2016-12-10 2018-06-29 高尚先 甘露糖在用于提高Treg细胞数量及其Foxp3因子表达水平的新用途
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
CN112384239A (zh) 2018-05-09 2021-02-19 芝加哥大学 影响免疫耐受的组合物和方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US891992A (en) 1907-06-27 1908-06-30 Henry Hess Method of forming conically-shaped ends upon rollers and other objects.
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US6248332B1 (en) * 1990-10-05 2001-06-19 Medarex, Inc. Targeted immunostimulation with bispecific reagents
MX9204131A (es) * 1991-07-16 1993-04-01 Bristol Myers Squibb Co Proteina receptora de gp120.
WO1995003234A1 (en) 1993-07-22 1995-02-02 Precision Valve Corporation Multi-directional actuation overcap
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
EP0759782A1 (en) 1994-05-26 1997-03-05 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness
US5548275A (en) * 1995-01-23 1996-08-20 Shambayati; Ali Alarm system for enclosing and protecting an area
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
EP0808366A1 (en) * 1995-01-31 1997-11-26 The Rockefeller University IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF
US5871964A (en) * 1996-07-15 1999-02-16 Incyte Pharmaceuticals, Inc. Human C-type lectin
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
US5935813A (en) * 1997-03-20 1999-08-10 Incyte Pharmaceuticals, Inc. Human pancreatitis-associated protein
AU7172198A (en) * 1997-04-29 1998-11-24 Incyte Pharmaceuticals, Inc. Human c-type lectin
JP2002512524A (ja) 1997-06-03 2002-04-23 財団法人相模中央化学研究所 膜貫通ドメインを有するヒト蛋白質及びそれをコードするｄｎａ
US6273443B1 (en) * 1998-06-01 2001-08-14 Sunrise Medical Hhg Inc. Universal elevating leg rest assembly
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
ATE486938T1 (de) * 1999-08-12 2010-11-15 Agensys Inc C-typ-lektin-transmembran-antigen, das in menschlichem prostatakrebs exprimiert wird, und verwendungen dieses antigens
EP1339830A2 (en) 2000-12-21 2003-09-03 Stichting Katholieke Universiteit Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes
US20030232745A1 (en) * 2001-06-26 2003-12-18 Olson William C. Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
US7022323B2 (en) * 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
CA2548317C (en) * 2003-12-09 2009-04-21 Synergy Microwave Corporation User-definable thermal drift voltage control oscillator

Also Published As

Publication number Publication date
US7285642B2 (en) 2007-10-23
US20080160041A1 (en) 2008-07-03
KR100952883B1 (ko) 2010-04-16
EP1086137B1 (en) 2008-06-11
KR20080098678A (ko) 2008-11-11
EP1516881A2 (en) 2005-03-23
JP5363432B2 (ja) 2013-12-11
JP2003502283A (ja) 2003-01-21
US8058400B2 (en) 2011-11-15
JP2010285450A (ja) 2010-12-24
CA2330231A1 (en) 2000-10-26
US8105599B2 (en) 2012-01-31
PT1516881E (pt) 2010-08-25
ES2307502T3 (es) 2008-12-01
US20050118168A1 (en) 2005-06-02
EP1046651A1 (en) 2000-10-25
ATE398140T1 (de) 2008-07-15
DK1516881T3 (da) 2010-09-27
AU4152600A (en) 2000-11-02
US20050220804A1 (en) 2005-10-06
CA2330231C (en) 2013-07-16
HK1036285A1 (en) 2001-12-28
NZ508723A (en) 2003-12-19
WO2000063251A1 (en) 2000-10-26
DK1086137T3 (da) 2008-10-27
DE60039151D1 (de) 2008-07-24
DE60044621D1 (de) 2010-08-12
EP1516881A3 (en) 2005-08-31
ATE472558T1 (de) 2010-07-15
AU776317B2 (en) 2004-09-02
US7148329B1 (en) 2006-12-12
KR20010071530A (ko) 2001-07-28
KR20070094990A (ko) 2007-09-27
PT1086137E (pt) 2008-09-09
JP4989820B2 (ja) 2012-08-01
KR100923340B1 (ko) 2009-10-22
EP1086137A1 (en) 2001-03-28
EP1516881B1 (en) 2010-06-30

Similar Documents

Publication Publication Date Title
ES2346877T3 (es) Composicion y procedimiento para modular la interaccion de las celulas t y las celulas dendriticas.
AU2019203823B2 (en) CS1-specific chimeric antigen receptor engineered immune effector cells
US7368535B2 (en) CD200 receptors
CN105884903A (zh) 靶向抗原呈递细胞的疫苗
TW201247700A (en) Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists
US20240197873A1 (en) Modified tumor-infiltrating lymphocyte and use thereof
AU4039999A (en) Antibodies to dendritic cells and human dendritic cell populations and uses thereof
US20090130144A1 (en) Direct vaccination of the bone marrow
WO1999017801A2 (en) Materials and methods relating to the stimulation of cells
Fayen et al. The expansion of human γδ T cells in response to Daudi cells requires the participation of CD4+ T cells
HK1036285B (en) Composition and method for modulating dendritic cell-t cell interaction
KR20250005247A (ko) Cmv-hiv 특이적 키메라 항원 수용체 t 세포
Crawford Human peripheral blood dendritic cells: phenotype, morphology, and function
CA2378477A1 (en) Induction of immune tolerance
ALTRICHTER et al. Workshop T Novel Strategies for Vaccination and Immunotherapy